WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. announced today that both ROTATEQ (rotavirus vaccine, live, oral, pentavalent) and GARDASIL [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine] have now been adopted by all 55 U.S.-based immunization projects of the Centers for Disease Control and Prevention’s (CDC) Vaccines for Children (VFC) program. The 55 Immunization Projects include the 50 states in addition to city programs in Washington DC, New York City, Philadelphia, Chicago, and San Antonio.
